What is #hpbcsm?
#hpbcsm is a disease hashtag submitted by @subatomicdoc
#hpbcsm healthcare social media hashtag
Related Hashtags
Latest Tweets
 | @BhaarathP10039 Top 10 GI Cancer Trials in May 2025 → BREAKWATER → CHECKMATE577 → NEOPAN → DESTINY-GASTRIC04 → CHALLENGE → CAIRO6 → CHECKMATE9DW → CHECKMATE8HW → KEYNOTE E27 → RAPIDO #Cancer #Oncology #MedTwitter #CancerResearch #CancerCare #crcsm #esocsm #hpbcsm #pancsm #LARVOL https://t.co/BzIBQsP0KQ |
| @BhaarathP10039 Post-@ASCO 2025: Most viewed GI Cancer oncologists on X #ASCO2025 #ASCO25 #Cancer #Oncology #MedTwitter #CancerResearch #CancerCare #ancsm #crcsm #esocsm #hpbcsm #pancsm #stcsm #LARVOL https://t.co/3dylhgOeq2 |
 | @mtmdphd Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies [May 10, 2024] @Amitmahipal79 et al. Cancers https://t.co/xONNaih4nc #PrecisionMedicine #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm https://t.co/EuT2CKVf80 |
 | @nativbklyn24 [REDACTED USER] https://t.co/LgSXxlFYx1 |
 | @realbowtiedoc @OncBrothers @GIcancerDoc @NVijayvergiaMD #GIonc session of @OncBrothers concludes with discussion of #NET sequencing, toxicities and the role of #PRRT and finishing with #hpbcsm with rich  new bitropics. Excellent work @GIcancerDoc and @NVijayvergiaMD #ASCO25 https://t.co/0YxY7uF452 |
 | @OncLive Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer #BiliaryTractCancer #hpbcsm https://t.co/H8qyiMgoyO |
| @BhaarathP10039 Bispecific Antibodies (BsAbs) in GI Cancers @ASCO #ASCO25 #ASCO2025 #BsAbs #Cancer #Oncology #ancsm #crcsm #esocsm #hpbcsm #pancsm #stcsm #LARVOL https://t.co/82dQxetRPX |
 | @CancerNetwrk Nivolumab plus ipilimumab significantly improved overall survival compared with lenvatinib or sorafenib in patients with previously untreated hepatocellular carcinoma. #hpbcsm #oncology https://t.co/ph7rhxhof1 |
| @BhaarathP10039 ADC trials in GI Cancer at @ASCO #ASCO2025 #ASCO25 #LARVOL #ancsm #crcsm #esocsm #hpbcsm #pancsm #stcsm https://t.co/jQht4ZyrdH |
| @BhaarathP10039 Pre-@ASCO 2025: GI Cancer oncologists to follow on X. #ancsm #crcsm #esocsm #hpbcsm #pancsm #stcsm #ASCO2025 #ASCO25 #LARVOL https://t.co/wDDDE026Pz |
 | @OncJournal '@Amitmahipal79 et al describe BRAF mut 4.4% of non #crcsm #GIonc cancers, #BRAFV600E most common #hpbcsm.  Liquid biopsy reliably detects #BRAF status showed mixed #OS, and use of BRAF inhibitors  despite approvals. '@doctorC369
https://t.co/ABudX9Kl8r https://t.co/OQA3DLPopu |
#hpbcsm content from Twitter.